Tepezza®

Understanding Tepezza®

Tepezza® is used to treat Thyroid Eye Disease (TED), also known as Graves’ orbitopathy. It is the first FDA-approved treatment specifically for TED and works by blocking the insulin-like growth factor-1 receptor (IGF-1R), which plays a key role in the inflammation and tissue expansion behind the eyes. By inhibiting IGF-1R, Tepezza® helps reduce inflammation and swelling in the eye muscles and surrounding tissues, leading to a reduction in bulging eyes (proptosis) and improved vision.

How Tepezza® Works:

• Blocks IGF-1R, a key driver of TED-related inflammation.
• Reduces swelling in eye muscles and tissues, improving symptoms.
• Shrinks bulging eyes (proptosis) and helps improve vision.

FDA Approval:

• Tepezza®: Approved on January 21, 2020

For more information, please visit the Tepezza® patient website and speak with your healthcare provider to determine if Tepezza® is the right treatment option for you.